Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
Deborah B. Horn, Donna H. Ryan, Sanja Giljanovic Kiš, Breno Edson Sendão Alves, Mu Yiming, Sin Gon Kim, Jens Aberle, Stephen C. Bain, Sheryl Allen, Elizabeth B. Sarker, Qiwei Wu, Adam Stefański, Irina Jouravskaya
Topics & Concepts
MedicineType 2 diabetesObesityInternal medicineDiabetes mellitusReceptorEndocrinologyPhase (matter)Clinical trialPhases of clinical researchMEDLINEDiabetes Treatment and ManagementRegulation of Appetite and ObesityMetabolism, Diabetes, and Cancer